The emergence of molecular classification in BC and the integration of novel treatment approaches, including neoadjuvant chemotherapy and CDK4/6 inhibitors, complicate the extrapolation of findings from previous studies to contemporary clinical practice. The gene discussed is CDK4; the disease is breast cancer.